Tristel (TSTL) H2 2025 TU earnings summary

Executive summary

• Achieved significant growth for the year ended 30 June 2025, with results in line with market expectations and strategic targets.

• Strong demand for infection prevention products, including robust performance in newly established North American markets.

• Board strengthened with the appointment of a new CFO joining in September.

Financial highlights

• Revenue increased by 11% year-over-year to £46.5m (FY 2024: £41.9m).

• Adjusted profit before tax up 23% to no less than £10.1m (FY 2024: £8.2m).

• Second half revenues rose 15% on a constant currency basis.

• Cash balances at year-end were £12.8m, up from £11.8m the previous year.

Outlook and guidance

• Confident in sustaining growth momentum into the next year, supported by strong demand and strategic leadership.

• Revenue growth target remains at 10–15% annually, with an EBITDA margin goal of at least 25%.